Ropinirole

Generic Name: Ropinirole

Brand Names: Requip

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₄N_₂O

CAS Number: 91374-21-9

Unique Ingredient Identifier: 030PYR8953

Background: Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome .

In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .

Indication: For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .

Associated Conditions: Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)

Clinical Trials

A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.

Phase 4

Conditions: Bipolar Disorder
Major Depressive Disorder

First Posted Date: 2006-06-09

Last Posted Date: 2006-06-09

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 60

Registration Number: NCT00335205

Locations: 🇮🇱
Chaim Sheba Medical Center, Dept. of Psychiatry, Tel Hashomer, Israel
🇮🇱
Jerusalem Mental Health Center, Jerusalem, Israel

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

Phase 4

Completed

Conditions: Sexual Dysfunction

First Posted Date: 2006-06-06

Last Posted Date: 2015-02-19

Lead Sponsor: St. Luke's-Roosevelt Hospital Center

Target Recruit Count: 9

Registration Number: NCT00334048

Locations: 🇺🇸
Mood Disorders Research Program, New York, New York, United States

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

Phase 3

Completed

Conditions: Parkinson Disease

First Posted Date: 2006-05-29

Last Posted Date: 2017-08-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 343

Registration Number: NCT00331149

Locations: 🇬🇧
GSK Investigational Site, Oxford, United Kingdom

Long-term Study Of Ropinirole In Restless Legs Syndrome

Phase 4

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Placebo
Drug: Ropinirole

First Posted Date: 2006-05-25

Last Posted Date: 2017-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 404

Registration Number: NCT00329602

Locations: 🇨🇭
GSK Investigational Site, Zürich, Switzerland

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

Phase 3

Completed

Conditions: Restless Legs Syndrome (RLS)
Restless Legs Syndrome

First Posted Date: 2006-04-17

Last Posted Date: 2016-10-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 568

Registration Number: NCT00314860

Locations: 🇬🇧
GSK Investigational Site, Ledbury, United Kingdom

Ropinirole in the Treatment of Bipolar Depression

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2006-04-17

Last Posted Date: 2017-04-18

Lead Sponsor: Cambridge Health Alliance

Target Recruit Count: 40

Registration Number: NCT00314821

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Cambridge Health Alliance, Cambridge, Massachusetts, United States

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

Not Applicable

Completed

Conditions: Depressive Disorder, Major

First Posted Date: 2006-02-02

Last Posted Date: 2008-05-19

Lead Sponsor: Stanford University

Target Recruit Count: 60

Registration Number: NCT00285727

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Depression Research Clinic, Psychiatry Department, Stanford School of Medicine, Stanford, California, United States